SB756050 is a selective TGR5 agonist. SB756050 has the potential for type 2 diabetes treatment.
体外研究
TGR5 is a bile acid receptor and a potential target for the treatment of type 2 diabetes (T2D).
体内研究
SB756050 is well‐tolerated; it is readily absorbed, exhibited nonlinear pharmacokinetics with a less than dose‐proportional increase in plasma exposure above 100 mg, and demonstrates no significant changes in exposure when co‐administered with sitagliptin. SB756050 demonstrates highly variable pharmacodynamic effects both within dose groups and between doses, with increases in glucose seen at the two lowest doses and no reduction in glucose seen at the two highest doses. The glucose effects of SB756050 sitagliptin are comparable to those of sitagliptin alone, even though gut hormone plasma profiles are different.
分子式
C21H28N2O8S2
分子量
500.59
CAS号
447410-57-3
运输条件
Room temperature in continental US; may vary elsewhere.